All In Biotech

Drug Trial Radar · NCT03952039

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

A Phase 3, Multicenter, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy (BAT) in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib

Last checked: Nov 21, 2026Latest source record: Aug 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 202 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

202

Actual

Start

Sep 9, 2019

Primary completion

Dec 15, 2022

Study completion Jul 28, 2025

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
First posted
May 16, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy (BAT) in subjects with DIPSS (Dynamic International Prognostic Scoring System)-intermediate or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF) and previously treated with ruxolitinib. The primary objective of the study is to evaluate the percentage of subjects with at least 35% spleen volume reduction in the fedratinib and the BAT arms.

Conditions

  • Primary Myelofibrosis
  • Post-Polycythemia Vera
  • Myelofibrosis

Interventions

  • FEDRATINIBDrug

    A potent and selective inhibitor of JAK2 kinase activity

  • Best Available Therapy (BAT)Drug

    Best available therapy (BAT)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Spleen Volume Response Rate (RR)Time frame: From Screening to end of Cycle 6 (1 cycle = 28 days), approximately 196 days

Locations

107 sites in 16 countries. Site status is shown where the registry gives one.

  • Local Institution - 100

    Melbourne, Australia

  • Local Institution - 103

    Darlinghurst, New South Wales, Australia

  • Local Institution - 101

    Adelaide, South Australia, Australia

  • Local Institution - 105

    Box Hill, Victoria, Australia

  • Local Institution - 102

    Langwarrin, Victoria, Australia

  • Local Institution - 156

    Graz, Austria

  • Local Institution - 154

    Innsbruck, Austria

  • Local Institution - 155

    Linz, Austria

  • Local Institution - 151

    Salzburg, Austria

  • Local Institution - 150

    Vienna, Austria

  • Local Institution - 152

    Vienna, Austria

  • Local Institution - 153

    Wels, Austria

  • Local Institution - 200

    Bruges, Belgium

  • Local Institution - 202

    Brussels, Belgium

  • Local Institution - 205

    La Louvière-(Haine St-Paul), Belgium

  • Local Institution - 201

    Leuven, Belgium

  • Local Institution - 204

    Liège, Belgium

  • Local Institution - 203

    Yvoir, Belgium

  • Local Institution - 555

    Beijing, China

  • Local Institution - 550

    Guangzhou, Guangdong, China

  • Local Institution - 553

    Tianjin, China

  • Local Institution - 557

    Zhengzhou, China

  • Local Institution - 700

    Brno, Czechia

  • Local Institution - 702

    Ostrava-Poruba, Czechia

  • Local Institution - 701

    Prague, Czechia

  • Local Institution - 255

    Angers, France

  • Local Institution - 256

    Brest, France

  • Local Institution - 254

    Lens, France

  • Local Institution - 259

    Lille, France

  • Local Institution - 260

    Nice, France

  • Local Institution - 250

    Nîmes, France

  • Local Institution - 252

    Paris, France

  • Local Institution - 258

    Pessac, France

  • Local Institution - 257

    Pierre-Bénite, France

  • Local Institution - 261

    Poitiers, France

  • Local Institution - 251

    Strasbourg, France

  • Local Institution - 253

    Toulouse, France

  • Local Institution - 302

    Aachen, Germany

  • Local Institution - 308

    Frankfurt am Main, Germany

  • Local Institution - 306

    Halle, Germany

Showing 40 of 107 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.